Key Takeaways
- Valent BioSciences and Seipasa have formed a strategic partnership to commercialize new biostimulant technologies in the U.S.
- The agreement grants Valent BioSciences exclusive rights to introduce Seipasa’s Sweetsei™ biostimulant to U.S. growers.
- Sweetsei™ is designed to enhance quality parameters in specialty crops through an optimized biochemical matrix.
- Leadership from both companies highlight scientific rigor and international market success as drivers of the collaboration.
- The partnership builds on Valent BioSciences’ growing biostimulant portfolio following its acquisition of FBSciences.
Valent BioSciences Forms Strategic Collaboration to Advance Biostimulants
Valent BioSciences announced a new strategic partnership with Seipasa to strengthen biostimulant offerings for U.S. agriculture. Seipasa, known internationally for its work in biopesticides, biostimulants and plant nutrition, has designated Valent BioSciences as its exclusive commercialization partner for innovative biostimulant technologies in the U.S. market.
The collaboration will introduce Sweetsei™, a next-generation biostimulant formulated to influence key plant pathways and improve crop quality in high-value specialty crops.
Salman Mir, President and CEO of Valent BioSciences, said the partnership reflects shared scientific standards and a commitment to delivering rigorously developed solutions to growers.
Valent BioSciences to Bring Sweetsei™ Biostimulant to U.S. Farmers
Sweetsei™ has demonstrated strong performance across global agricultural markets, including Latin America, Europe and Africa. The product leverages an optimized biochemical matrix designed to enhance plant development and improve quality parameters, offering growers a new tool to support crop performance.
Pedro Peleato, CEO of Seipasa, noted that entering the U.S. market through the partnership is an important step in the company’s global expansion, citing Sweetsei’s proven track record internationally.
The introduction of Sweetsei™ complements Valent BioSciences’ broader biostimulant strategy. Since 2022, the company has invested in its dedicated biostimulant business unit, and in 2023 it expanded its portfolio through the acquisition of FBSciences, adding the Transit® product line.
Strengthens Position in U.S. Biologicals Market
The new collaboration positions the company to further expand its presence in the biologicals sector at a time of rising demand for crop quality, sustainability and science-driven solutions. By integrating Seipasa’s technology into its portfolio, the company aims to deliver additional value for U.S. growers seeking advanced biostimulant options.
